Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin

J. Pettus, B. Mcnabb, R. H. Eckel, Jay S Skyler, A. Dhalla, S. Guan, P. Jochelson, L. Belardinelli, R. H. Henry

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Aim: To report the results of two phase III trials assessing the efficacy of ranolazine for glycaemic control in patients with type 2 diabetes on metformin or glimepiride background therapy. Methods: In two double-blind trials we randomized 431 and 442 patients with type 2 diabetes to ranolazine 1000mg twice daily versus placebo added to either glimepiride (glimepiride add-on study) or metformin background therapy (metformin add-on study). Patients receiving ranolazine added to metformin had their metformin dose halved (with the addition of a metformin-matched placebo) relative to the placebo group to correct for a metformin-ranolazine pharmacokinetic interaction. The primary endpoint of the trials was the change from baseline in glycated haemoglobin (HbA1c) at week 24. Results: When added to glimepiride, ranolazine caused a 0.51% least squares mean [95% confidence interval (CI) 0.71, 0.32] decrease from baseline in HbA1c at 24weeks relative to placebo and roughly doubled the proportion of patients achieving an HbA1c of

Original languageEnglish (US)
Pages (from-to)463-474
Number of pages12
JournalDiabetes, Obesity and Metabolism
Volume18
Issue number5
DOIs
StatePublished - May 1 2016
Externally publishedYes

Fingerprint

glimepiride
Metformin
Type 2 Diabetes Mellitus
Placebos
Glycosylated Hemoglobin A
Ranolazine
Least-Squares Analysis
Pharmacokinetics

Keywords

  • Antidiabetic drug
  • Clinical trial
  • Glycaemic control
  • Randomized trial
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin. / Pettus, J.; Mcnabb, B.; Eckel, R. H.; Skyler, Jay S; Dhalla, A.; Guan, S.; Jochelson, P.; Belardinelli, L.; Henry, R. H.

In: Diabetes, Obesity and Metabolism, Vol. 18, No. 5, 01.05.2016, p. 463-474.

Research output: Contribution to journalArticle

Pettus, J, Mcnabb, B, Eckel, RH, Skyler, JS, Dhalla, A, Guan, S, Jochelson, P, Belardinelli, L & Henry, RH 2016, 'Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin', Diabetes, Obesity and Metabolism, vol. 18, no. 5, pp. 463-474. https://doi.org/10.1111/dom.12629
Pettus, J. ; Mcnabb, B. ; Eckel, R. H. ; Skyler, Jay S ; Dhalla, A. ; Guan, S. ; Jochelson, P. ; Belardinelli, L. ; Henry, R. H. / Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin. In: Diabetes, Obesity and Metabolism. 2016 ; Vol. 18, No. 5. pp. 463-474.
@article{4ef7a2e2fdb94c40b15d9fdf1b28ab71,
title = "Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin",
abstract = "Aim: To report the results of two phase III trials assessing the efficacy of ranolazine for glycaemic control in patients with type 2 diabetes on metformin or glimepiride background therapy. Methods: In two double-blind trials we randomized 431 and 442 patients with type 2 diabetes to ranolazine 1000mg twice daily versus placebo added to either glimepiride (glimepiride add-on study) or metformin background therapy (metformin add-on study). Patients receiving ranolazine added to metformin had their metformin dose halved (with the addition of a metformin-matched placebo) relative to the placebo group to correct for a metformin-ranolazine pharmacokinetic interaction. The primary endpoint of the trials was the change from baseline in glycated haemoglobin (HbA1c) at week 24. Results: When added to glimepiride, ranolazine caused a 0.51{\%} least squares mean [95{\%} confidence interval (CI) 0.71, 0.32] decrease from baseline in HbA1c at 24weeks relative to placebo and roughly doubled the proportion of patients achieving an HbA1c of",
keywords = "Antidiabetic drug, Clinical trial, Glycaemic control, Randomized trial, Type 2 diabetes",
author = "J. Pettus and B. Mcnabb and Eckel, {R. H.} and Skyler, {Jay S} and A. Dhalla and S. Guan and P. Jochelson and L. Belardinelli and Henry, {R. H.}",
year = "2016",
month = "5",
day = "1",
doi = "10.1111/dom.12629",
language = "English (US)",
volume = "18",
pages = "463--474",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin

AU - Pettus, J.

AU - Mcnabb, B.

AU - Eckel, R. H.

AU - Skyler, Jay S

AU - Dhalla, A.

AU - Guan, S.

AU - Jochelson, P.

AU - Belardinelli, L.

AU - Henry, R. H.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Aim: To report the results of two phase III trials assessing the efficacy of ranolazine for glycaemic control in patients with type 2 diabetes on metformin or glimepiride background therapy. Methods: In two double-blind trials we randomized 431 and 442 patients with type 2 diabetes to ranolazine 1000mg twice daily versus placebo added to either glimepiride (glimepiride add-on study) or metformin background therapy (metformin add-on study). Patients receiving ranolazine added to metformin had their metformin dose halved (with the addition of a metformin-matched placebo) relative to the placebo group to correct for a metformin-ranolazine pharmacokinetic interaction. The primary endpoint of the trials was the change from baseline in glycated haemoglobin (HbA1c) at week 24. Results: When added to glimepiride, ranolazine caused a 0.51% least squares mean [95% confidence interval (CI) 0.71, 0.32] decrease from baseline in HbA1c at 24weeks relative to placebo and roughly doubled the proportion of patients achieving an HbA1c of

AB - Aim: To report the results of two phase III trials assessing the efficacy of ranolazine for glycaemic control in patients with type 2 diabetes on metformin or glimepiride background therapy. Methods: In two double-blind trials we randomized 431 and 442 patients with type 2 diabetes to ranolazine 1000mg twice daily versus placebo added to either glimepiride (glimepiride add-on study) or metformin background therapy (metformin add-on study). Patients receiving ranolazine added to metformin had their metformin dose halved (with the addition of a metformin-matched placebo) relative to the placebo group to correct for a metformin-ranolazine pharmacokinetic interaction. The primary endpoint of the trials was the change from baseline in glycated haemoglobin (HbA1c) at week 24. Results: When added to glimepiride, ranolazine caused a 0.51% least squares mean [95% confidence interval (CI) 0.71, 0.32] decrease from baseline in HbA1c at 24weeks relative to placebo and roughly doubled the proportion of patients achieving an HbA1c of

KW - Antidiabetic drug

KW - Clinical trial

KW - Glycaemic control

KW - Randomized trial

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84959440759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959440759&partnerID=8YFLogxK

U2 - 10.1111/dom.12629

DO - 10.1111/dom.12629

M3 - Article

C2 - 26749407

AN - SCOPUS:84959440759

VL - 18

SP - 463

EP - 474

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 5

ER -